EU Council Adopts Pharma Package, Sends It to Parliament

The Council of the European Union formally adopted its position at first reading on 28 September 2026 on the new Regulation and Directive that would replace the EU's core pharmaceutical law, in place largely unchanged since 2004. The texts now move to the European Parliament for a second reading — the next, and likely final, legislative checkpoint before a framework that has governed EU medicines authorisation for two decades is rewritten.

What moved, and why an agriculture council adopted a medicines law

The 28 September adoption is a procedural step more than a substantive one: by this stage, the texts had already been politically agreed. A provisional agreement between the Council and the European Parliament's negotiators was reached on 11 December 2025, and the Committee of Permanent Representatives — COREPER, the body that vets Council business before ministers sign off — endorsed it on 6 March 2026. Formal adoption at first reading on 28 September simply ratified that agreement in the Council's own procedure, and it happened as an 'A item', the EU's label for business so settled that it needs no debate when ministers meet. That it was taken up at a meeting of the Agriculture and Fisheries Council, rather than a health-focused configuration, is a quirk of EU scheduling, not a substantive signal: A items are frequently adopted at whichever Council meeting is next on the calendar, regardless of its nominal subject.

What the package actually changes

• A new Regulation laying down Union procedures for the authorisation and supervision of medicinal products for human use, and rules governing the European Medicines Agency — replacing scattered amendments to the current framework with a consolidated text.
• A new Directive repealing Directive 2001/83/EC, the Union code on medicinal products that has anchored EU pharma law since 2001, and Directive 2009/35/EC.
• Regulatory data protection: a baseline eight-year period during which a company holds exclusive rights to the pre-clinical and clinical trial data behind a new medicine, with the package's broader design allowing additional protection tied to conditions such as EU-wide launch commitments.
• An antimicrobial-resistance incentive: a transferable exclusivity voucher for developers of priority antibiotics, redeemable for one additional year of market protection on a product of the holder's choice — blocked, under the Council's proposed 'blockbuster clause', from use on any product with more than €490 million in annual gross sales across the preceding four years.

What is still unresolved

Two things are not yet settled, and RA/QA teams tracking this file should treat both as open. First, the European Parliament still has to act: the Council's position goes to a second reading, and while multiple legal-sector sources describe the vote as expected this autumn, published estimates for the specific plenary date conflict — some point to mid-October, others to later in the season. Regulatory News found no single date corroborated across independent outlets strongly enough to print as fact, so none appears above; check the Parliament's own plenary calendar for the current schedule. Second, even after Parliament acts, the legislation needs formal signature and publication in the Official Journal of the European Union before it enters into force, with transitional periods still to run before most obligations bind. The 28 September adoption is a major, concrete step in a reform billed as the biggest in 20 years — it is not the law taking effect.

Frequently asked questions

What did the Council of the EU adopt on 28 September 2026?

Its first-reading position on a new Regulation governing medicines authorisation and EMA, and a new Directive repealing Directive 2001/83/EC and Directive 2009/35/EC, adopted as uncontested A items at a meeting of the Agriculture and Fisheries Council.

What happens next?

The European Parliament takes up the texts at second reading. Sources disagree on the exact plenary-vote date, so none is stated here as confirmed.

What changes under the package?

A baseline eight-year data-protection period for new medicines, and a transferable exclusivity voucher giving priority-antibiotic developers one extra year of market protection on a chosen product, capped by a €490 million blockbuster clause.

How significant is this reform?

Widely described as the most comprehensive revision of EU pharmaceutical legislation in over 20 years, replacing the framework in place since 2004. The underlying political agreement was reached 11 December 2025 and endorsed by COREPER on 6 March 2026.